{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T10:22:48Z","timestamp":1784024568035,"version":"3.55.0"},"reference-count":56,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T00:00:00Z","timestamp":1661299200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI16\/01525"],"award-info":[{"award-number":["PI16\/01525"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Annals of Neurology"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>We aimed (1) to analyze salivary calcitonin gene\u2010related peptide (CGRP) levels in patients with migraine, (2) to predict erenumab response from baseline CGRP levels, and (3) to evaluate CGRP change post\u2010treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This is a prospective observational study that measured salivary CGRP levels in healthy controls (HCs), patients with episodic migraine (EM) and patients with chronic migraine (CM). Participants collected saliva samples at baseline and, the patients who were candidates to receive erenumab, also collected saliva after 3 doses of treatment. We quantified CGRP\u2010like immunoreactivity (CGRP\u2010LI) by enzyme\u2010linked immunosorbent assay (ELISA) and we performed an analysis at baseline and post\u2010treatment through generalized linear mixed models.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>At baseline, a higher headache frequency was associated with higher CGRP levels, those being even higher in the presence of depressive symptoms. A cutoff point (mean, 95% confidence interval [CI]) of 103.93 (95% CI\u00a0=\u00a0103.35\u2013104.51) pg\/ml was estimated to differentiate migraine from controls with an area under the receiver operating characteristic (ROC) curve (AUC, 95% CI) of 0.801 (95% CI\u00a0=\u00a00.798\u20130.804). We also found that higher pretreatment salivary CGRP levels were statistically significantly associated to a higher probability of having 50% or greater reduction in headache frequency in patients with EM, but not in patients with CM. After 12\u2009weeks of treatment with erenumab, salivary CGRP levels from patients within all spectrum of migraine frequency converged to similar CGRP values. In contrast, in patients with concomitant depressive symptoms, this convergence did not happen.<\/jats:p><\/jats:sec><jats:sec><jats:title>Interpretation<\/jats:title><jats:p>Patients with migraine not only have higher CGRP levels compared with HCs, but also the presence of depressive symptoms seems to increase salivary CGRP levels and we have evidence, for the first time, that baseline salivary CGRP concentration is associated with treatment response to erenumab. ANN NEUROL 2022;92:846\u2013859<\/jats:p><\/jats:sec>","DOI":"10.1002\/ana.26472","type":"journal-article","created":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T02:45:00Z","timestamp":1659926700000},"page":"846-859","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":63,"title":["Salivary <scp>CGRP<\/scp> and Erenumab Treatment Response: Towards Precision Medicine in Migraine"],"prefix":"10.1002","volume":"92","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5296-9401","authenticated-orcid":false,"given":"Alicia","family":"Alpuente","sequence":"first","affiliation":[{"name":"Headache Clinic, Neurology Department Vall d'Hebron University Hospital  Barcelona Spain"},{"name":"Headache and Neurological Pain Research Group, Vall d'Hebron Research Institute, Departament de Medicina Universitat Aut\u00f2noma de Barcelona  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor J","family":"Gallardo","sequence":"additional","affiliation":[{"name":"Headache and Neurological Pain Research Group, Vall d'Hebron Research Institute, Departament de Medicina Universitat Aut\u00f2noma de Barcelona  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laila","family":"Asskour","sequence":"additional","affiliation":[{"name":"Headache and Neurological Pain Research Group, Vall d'Hebron Research Institute, Departament de Medicina Universitat Aut\u00f2noma de Barcelona  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Caronna","sequence":"additional","affiliation":[{"name":"Headache Clinic, Neurology Department Vall d'Hebron University Hospital  Barcelona Spain"},{"name":"Headache and Neurological Pain Research Group, Vall d'Hebron Research Institute, Departament de Medicina Universitat Aut\u00f2noma de Barcelona  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Torres\u2010Ferrus","sequence":"additional","affiliation":[{"name":"Headache Clinic, Neurology Department Vall d'Hebron University Hospital  Barcelona Spain"},{"name":"Headache and Neurological Pain Research Group, Vall d'Hebron Research Institute, Departament de Medicina Universitat Aut\u00f2noma de Barcelona  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Pozo\u2010Rosich","sequence":"additional","affiliation":[{"name":"Headache Clinic, Neurology Department Vall d'Hebron University Hospital  Barcelona Spain"},{"name":"Headache and Neurological Pain Research Group, Vall d'Hebron Research Institute, Departament de Medicina Universitat Aut\u00f2noma de Barcelona  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,8,24]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30322-3"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-020-01208-0"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102417738202"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32162-0"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.12174"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410280213"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-018-0003-1"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13211"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3959(00)00232-3"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2006.09.017"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182a6cb72"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.20605"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102415625614"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102419856640"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2006.00294.x"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2009.01523.x"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.12250"},{"key":"e_1_2_8_19_1","first-page":"119","article-title":"Salivary CGRP can monitor the different migraine phases: CGRP (in)dependent attacks","volume":"42","author":"Alpuente A","year":"2021","journal-title":"Cephalalgia"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32504-8"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-017-0750-1"},{"key":"e_1_2_8_22_1","first-page":"1","volume-title":"Informe de posicionamiento terap\u00e9utico Erenumab","author":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios","year":"2019"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.56.suppl_1.S20"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102410379890"},{"key":"e_1_2_8_25_1","volume-title":"San Antonio Psychol Corp","author":"Beck A","year":"1996"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1037\/0022-006X.56.6.893"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-21131-4"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0024-3205(96)00627-3"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/2041-210X.12504"},{"key":"e_1_2_8_30_1","first-page":"1","article-title":"A kenward\u2010roger approximation and parametric bootstrap methods for tests in linear mixed models\u2013the R package pbkrtest","volume":"2014","author":"Halekoh U","year":"2014","journal-title":"J Stat Softw"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-018-0883-x"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102409351807"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2004.07.035"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2009.192492"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.12195"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41431-018-0150-2"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aap8757"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00034.2013"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-019-0216-y"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-017-0250-5"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1017\/neu.2018.31"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep12559"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0278-5846(01)00219-6"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbih.2022.100453"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2022.02.017"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2018.05.029"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30083-2"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000252808.97649.21"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102414547138"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2014.20.1.22"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000323925.29520.e7"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102420983282"},{"key":"e_1_2_8_53_1","unstructured":"Amgen Inc. Erenumab (Aimovig\u2122):US prescribing information.2018.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/761077s000lbl.pdf. Accessed Feb 21 2021."},{"key":"e_1_2_8_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00409-9"},{"key":"e_1_2_8_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2019.04.012"},{"key":"e_1_2_8_56_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-020-01193-4"},{"key":"e_1_2_8_57_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.1990.1001039.x"}],"container-title":["Annals of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ana.26472","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ana.26472","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ana.26472","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T10:19:19Z","timestamp":1692699559000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ana.26472"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,24]]},"references-count":56,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["10.1002\/ana.26472"],"URL":"https:\/\/doi.org\/10.1002\/ana.26472","archive":["Portico"],"relation":{},"ISSN":["0364-5134","1531-8249"],"issn-type":[{"value":"0364-5134","type":"print"},{"value":"1531-8249","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,24]]},"assertion":[{"value":"2022-04-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}